IMPROVEMENT IN METABOLIC RISK FACTORS FOR CVD – (05-08-05)

Effect of orlistat on cardiovascular disease risk in obese adults

Just so you know–it wasn’t me that designated April/May as “beat up the pharmaceuticals for obesity” months.

This study found improvements in several metabolic risk factors for CVD, but not enough to lower 10-year risk assessment.  Interestingly, although the patients on orlistat had lower total cholesterol, none reduced their cholesterol lowering meds.  I can practically guarantee that lifestyle changes geared towards a healthy body composition will definitely lower a patient’s need for cholesterol lowering drugs.

Read entire article here

For more than a decade, Dr. Bogash has stayed current with the medical literature as it relates to physiology, disease prevention and disease management. He uses his knowledge to educate patients, the community and cyberspace on the best way to avoid and / or manage chronic diseases using lifestyle and targeted supplementation.







Email: